Shilpa Pharma Lifesciences Limited, Unit-1, ANVISA Audit from Brazil
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Medicare's wholly-owned subsidiary, Shilpa Pharma Lifesciences Limited (Unit-1), successfully completed a GMP inspection by ANVISA, Brazil's health regulatory authority. The audit took place from June 30 to July 4, 2025, and concluded with no critical or major observations. Only minor procedural recommendations were noted, which the company plans to address through a CAPA plan within required timelines. This confirms the facility meets Brazilian GMP standards and can continue to supply pharmaceutical products to the Brazilian market.
Positive for shareholders — successful clearance with no critical or major observations from a key international regulator (Brazil/ANVISA) supports uninterrupted exports to Latin America and reinforces the company's regulatory compliance track record. This typically strengthens credibility for further approvals and business from regulated markets.